Composition of herbal therapeutics for the treatment of cardiovascular diseases

Abstract

Phytotherapeutic composition for the treatment of cardiovascular diseases, including: 10-30% by weight of a flavonoid-rich extract obtained from Ginkgo biloba and standardized to contain at least 90% pure flavonoid content; 5-20% w / w of a terpenoid-rich extract obtained from hawthorn berries (Crataegus oxyacantha) and standardized to contain at least 85% pure terpenoid content; 15-25% by weight of a complex of polyunsaturated fatty acids obtained from Perilla frutescens seeds, which has a ratio of omega-3 to omega-6 fatty acids of 3:1; 10-20 wt% of a polyphenolic extract from leaves of green tea (Camellia sinensis), standardized to a content of at least 95% pure polyphenols; 5-15 wt% of a nitric oxide-enhancing alkaloid extract from beetroot (Beta vulgaris), standardized to a content of at least 80% pure alkaloids; 4-12 wt% of an extract from Terminalia arjuna, rich in flavonoids and triterpenoids to improve cardiac function and reduce oxidative stress; 3-15% w / w of an extract from Withania somnifera containing withanolides to lower blood pressure and cholesterol levels; 2-10 wt% of an extract from Ocimum sanctum, containing eugenol and rosmarinic acid, which have anti-inflammatory and antiplatelet effects; 4-12 wt% of an extract from Punica granatum, providing polyphenols and ellagitannins to improve endothelial function; 2-10% w / w of a soluble fiber complex derived from psyllium husks (Plantago ovata) to improve bioavailability and gastrointestinal tolerability; and a pharmaceutically acceptable carrier or excipient selected from the group consisting of microcrystalline cellulose, magnesium stearate and silicon dioxide.

Description

FIELD OF THE INVENTIONThe present invention relates to a phytotherapeutic composition for preventing and treating cardiovascular diseases. The composition comprises standardized plant extracts, bioactive compounds and pharmaceutically acceptable carriers which synergistically contribute to cardiovascular health.The composition uses a combination of natural plant extracts, bioactive compounds and pharmaceutically acceptable carriers that act synergetically to improve cardiovascular function, regulate lipid metabolism, improve endothelium health and alleviate oxidative stress. This invention is of particular importance to persons at risk for cardiovascular diseases who seek an alternative to synthetic drugs with possible side effects. The formulation also focuses on improving bioavailability by advanced methods of administration such as nanoemulsion or liposomal encapsulation to ensure optimum therapeutic efficacy.More particularly, the present invention relates to the composition of phytotherapeutic compounds for treating cardiovascular diseases.BACKGROUND OF THE INVENTIONThe article treated in the background section should not be considered to be prior art solely because of its mention in the background section. Likewise, it should not be assumed that a problem mentioned in the background section or associated with the subject matter of the background section has already been recognized in the prior art. The subject matter of the background section merely represents various approaches, which may likewise be inventions per se.Cardiovascular diseases are still the major cause of morbidity and mortality worldwide and contribute to a considerable burden on public health. These diseases are due to several factors including poor nutrition, lack of exercise, genetic predisposition and oxidative stress. Conventional treatment of cardiovascular diseases comprises primarily the use of drugs such as statins, beta blockers, anticoagulants and blood pressure genes. These treatments, while effective, often risk undesirable effects such as liver toxicity, muscle damage, gastrointestinal discomfort, and increased bleeding propensity.In response to these concerns, interest in plant therapies that offer cardioprotective advantages with minimal side effects is growing. Several bioactive plant materials such as flavonoids, polyphenols, terpenoids and essential fatty acids have been studied in detail for their ability to improve cardiovascular health. These compounds exert several positive effects including anti-inflammatory, antioxidant, vasodilating, lipid lowering and antihypertensive effects.Despite the known advantages of individual plant extracts, the lack of standardized formulations has restricted their therapeutic application. The present invention overcomes this challenge by developing a novel phytotherapeutic composition that combines carefully selected plant extracts in precise proportions to maximize synergistic effects. Standardization of the bioactive compounds ensures consistent effectiveness, while innovative formulation techniques improve bioavailability and targeted delivery of these bioactive agents. This composition offers a scientifically validated, natural approach for the prevention and treatment of cardiovascular diseases without the risks associated with synthetic drugs.SUMMARYBefore describing the present systems and methods, it should be appreciated that this application is not limited to the described systems and methods, as there may be several possible embodiments that are not expressly depicted in the present disclosure. It is also to be understood that the terminology used in the specification is for the purpose of describing particular versions or embodiments only and is not intended to limit the scope of the present application.The present invention provides a phytotherapeutic composition comprising: a) 10-30% by weight of a flavonoid-rich extract derived from Ginkgo bilobaand standardized to contain at least 90% pure flavonoid content; b) 5-20% by weight of a terpenoid-rich extract derived from Crataegus oxyacantha(hawthorn berries) and standardized to contain at least 85% pure terpenoid content; c) 15-25% by weight of a polyunsaturated fatty acid complex derived from Perilla frutescensseat at a ratio of 3:1 omega-3 to omega-6 fatty acids; d) 10-20 wt.% of a polyphenolic extract from Camellia sinensis(green tea leaves), standardized to a content of at least 95% pure polyphenols; e) 5-15 wt.% of a nitric oxide-enhancing alkaloid extract from Beta vulgaris(red beet), standardized to a content of at least 80% pure alkaloids; f) 4-12 wt.% of an extract from Terminalia arjuna, which is rich in flavonoids and triterpenoids, for improving heart function and for reducing oxidative stress; g) 3-15 wt.% of an extract from Withania somnifera, which contains Withanolides for reducing hypertension and cholesterol levels; h) 2-10 wt% of an extract of Ogirum sanctum containing eugenol and rosmarinic acid and having anti-inflammatory activity and antiplatelet aggregation; i) 4-12 wt% of an extract of Punica granatum containing polyphenols and ellagitannin to improve endothelial function; j) 2-10 wt% of a soluble dietary fiber complex derived from Plantago ovata (Flohseed shells) to improve bioavailability and gastrointestinal compatibility; and k) a pharmaceutically acceptable carrier or excipient selected from the group consisting of microcrystalline cellulose,The magnesium stearate and silica are selected from magnesium stearate and silica.The composition may also contain:• 1-5 wt% coenzyme Q10to increase mitochondrial energy;• 2-6 weight percent omega-3 fatty acids to regulate lipid profile;• 0.1-1 wt% vitamin K2 (menaquinone-7) for arterial flexibility and calcium regulation.The composition can be formulated in the form of tablets, capsules, oral suspensions or effervescent powders, encapsulation in liposomes or nano-emulsions improving bioavailability and targeted administration.DETAILED DESCRIPTIONThe present invention relates to the composition of phytotherapeutic compounds for the treatment of cardiovascular diseases.The present invention provides a phytotherapeutic composition comprising: a) flavonoid rich extract from Ginkgo biloba(10-30 wt%) standardized to a level of at least 90% pure flavonoids. This extract is known for its strong antioxidant properties, which contribute to reducing oxidative stress and to improving vascular blood circulation. b) Terpenoid-rich extract from whitethorn berries (Crataegus oxyacantha) (5-20 wt %) standardized to a content of at least 85% pure terpenoids. The white spike is widely known for its role in improving cardiac output, lowering blood pressure and reducing cholesterol level. c) Polyunsaturated fatty acid complex from Perilla frutescensseed (15-25 wt%) having an omega-3 to omega-6 fatty acid ratio of 3:1. The presence of these essential fatty acids contributes to the protection of the cardiovascular system by reducing triglycerides, improving lipid metabolism and reducing inflammation. d) Green tea leaf polyphenol extract (Camellia sinensis) (10-20 wt.%) standardized to a content of at least 95% pure polyphenols. The green tea polyphenols are known to improve endothelial function, reduce arterial stiffness and have a strong antioxidant effect. e) Red beet nitric oxide-enhancing alkaloid extract (beta vulgaris) (5-15 wt%) standardized to a level of at least 80% pure alkaloids. The red-beet extract increases nitric oxide levels, promotes vasodilatation and improves blood circulation, thereby lowering blood pressure. f) Terminalia arjunaextract (4-12% by weight) rich in flavonoids and triterpenoids. Terminalia arjunais traditionally used to improve cardiac function, reduce oxidative stress and increase myocardium. g) Withania somniferaextract (Ashwagandha)(3-15 weight percent) containing Withanolide. Ashwagandha helps in stress management, reduces hypertension and regulates cholesterol level, contributing to general cardiovascular well-being. h) Oximuum sanctum (Heiige Basil) extract (2-10 wt%) containing eugenol and rosmarinic acid. These bioactive compounds have anti-inflammatory and platelet aggregation inhibiting effects and reduce the risk of clot formation and cardiovascular events. i) Extract of Punica granatum (pomegranate) (4-12 weight percent) containing polyphenols and ellagitannins. Pomegranate extract has been shown to improve endothelial function, decrease arterial plaque deposition and increase antioxidant activity. j) Soluble dietary fiber complex from flea seed shells (Plantago ovata) (2-10 wt%) which contributes to improving bioavailability and gastrointestinal compatibility. Psyllium husk contributes to lowering cholesterol levels and regulating blood sugar levels and promotes heart health. k) A pharmaceutically acceptable carrier or excipient selected from the group consisting of microcrystalline cellulose, magnesium stearate and silica which provides stability and proper delivery of the composition.In addition, the composition may contain:• Coenzyme Q10 (1-5 wt %) for increasing mitochondrial energy and for improving cardiac function.• Omega-3 fatty acids (2-6 weight percent) for regulating lipid profile and reducing inflammation.• Vitamin K2 (menaquinone-7) (0.1-1 wt%) for flexibility of arteries and regulation of calcium level to prevent arterial calcification. Advantages of Composition: 1. synergistic cardioprotective effects: The combination of multiple bioactive plant extracts enhances overall cardiovascular health by several mechanisms including improvement in blood circulation, reduction in oxidative stress, and improvement in lipid metabolism. 2. improved bioavailability: The inclusion of psyllium husk and advanced delivery mechanisms such as nano-emulsions or liposomal encapsulation ensures better absorption and efficacy. 3. natural and safe alternative: Compared to synthetic cardiovascular drugs, this phytotherapeutic composition provides a safer, natural alternative with fewer side effects. 4. Overall management of cardiovascular diseases: The composition targets several cardiovascular risk factors including hypertension, hyperlipidemia, atherosclerosis and oxidative stress.The phytotherapeutic composition of the present invention is developed by an optimized extraction and formulation process which ensures maximum efficacy and bioavailability of the active ingredients.Preparation: Preparation:1. Extraction of Bioactive Compounds extracts from Ginkgo biloba, Crataegus oxyacantha, Perilla frutescens, Camellia sinensis, Beta vulgaris, Terminalia arjuna, Withania somnifera, Ogirum sanctum and Punica garnetum are obtained by aqueous or hydroalcoholic extraction methods. The extracts are standardized to ensure a consistent bioactive content.2. Formulation of the composition The extracted bioactive compounds are mixed with coenzyme Q10, omega-3 fatty acids and vitamin K2. The mixture is processed to suitable dosage forms such as tablets, capsules or powder formulations.3. Improvement of stability and bioavailability The formulation is freeze dried or spray dried to increase stability and shelf life. Nanoemulsification or liposomal encapsulation is used to improve the absorption and targeted delivery of the active agents.The phytotherapeutic composition of the present invention is for the prevention and treatment of hypertension atherosclerosis myocardial infarctionThis is determined by the determination of strokeHyperlipidemia.EXAMPLESExample 1: Tablet Formulation A tablet formulation was prepared by mixing:• Ginkgo bilobaextract (20 wt %)• Crataegus oxyacantha extract (10 wt %)• Perilla frutescens oil (20 weight percent)• Extract from Camellia sinensis(15 wt%)• Beta vulgaris extract (10% by weight)• Terminalia arjunaextract (8 wt%)• Extract from Withania somnifera(7% by weight)• Ogiimum sanctumextract (5 wt%)• Extract of Punica garnetum (7 wt%)• Plantago ovata fiber (8 weight percent)• Microcrystalline cellulose and magnesium stearate as adjuvants. The mixture was compressed into tablets to ensure uniform distribution of the active ingredients.Example 2: Capsule Formulation A soft gel capsule was prepared by encapsulating a liquid mixture of:• Perilla frutescens oil (22 weight percent)• Coenzyme Q10 (3 weight percent)• Omega-3 fatty acids (4% by weight)• Vitamin K2 (0.5 wt%)• Extracts from Ginkgo biloba, Crataegus oxyacantha, Camellia sinensis, Beta vulgaris, Terminalia arjuna, Withania somnifera, Ociimum sanctum and Punica garnetum.

Claims

A phytotherapeutic composition for the treatment of cardiovascular diseases comprising: 10-30% by weight of a flavonoid-rich extract derived from Ginkgo biloba and standardized to contain at least 90% pure flavonoid content; 5-20% by weight of a terpenoid-rich extract derived from barnacleberries (Crataegus oxyacantha) and standardized to contain at least 85% pure terpenoid content; 15-25% by weight of a polyunsaturated fatty acid complex derived from Perilla frutescens seed and having an omega-3 to omega-6 fatty acid ratio of 3:1; 10-20 wt.% of green tea leaf polyphenolic extract (Camellia sinensis) standardized to a content of at least 95% pure polyphenols; 5-15 wt.% of red beet nitric oxide-enhancing alkaloid extract (Beta vulgaris) standardized to a content of at least 80% pure alkaloids; 4-12 wt.% of Terminalia arjuna extract rich in flavonoids and triterpenoids to improve cardiac function and reduce oxidative stress; 3-15 wt.% of Wittiga extract containing Withanolides to reduce hypertension and cholesterol levels; 2-10 wt% of an extract of Ogirum sanctum containing eugenol and rosmarinic acid which are anti-inflammatory and anti-platelet active; 4-12 wt% of an extract of Punica granatum which provides polyphenols and ellagitannins for improving endothelial function; 2-10 wt% of a soluble dietary fiber complex derived from Floh seed shells (Plantago ovata) to improve bioavailability and gastrointestinal compatibility; and a pharmaceutically acceptable carrier or excipient selected from the group consisting of microcrystalline cellulose, magnesium stearate and silica.The composition of claim 1, wherein the polyunsaturated fatty acid complex of Perilla frutescens is present at a concentration of 18-22% by weight to optimize lipid regulation and cardiovascular function.The composition of claim 1, wherein the red bet nitric oxide enhancing alkaloid extract is present at a concentration of 8-12 wt% to enhance vasodilatation and enhance blood circulation.The composition of claim 1, further comprising: 1-5 wt% coenzyme Q10 to increase mitochondrial energy; 2-6 weight percent omega-3 fatty acids to regulate lipid profile; and 0.1-1 wt% vitamin K2 (menaquinone-7) for arterial flexibility and calcium regulation.The composition of claim 1, wherein the extract from Oximmum sanctum is enriched with at least 5% eugenol to enhance cardiovascular benefits.The composition of claim 1, wherein the formulation is encapsulated in liposomes or nano-emulsions to improve bioavailability and targeted delivery.The composition of claim 1, wherein the therapeutic use of the composition is for preventing and treating hypertension, atherosclerosis, myocardial infarction, stroke, and hyperlipidemia.